Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. - Sharman JP; Forero-Torres A; Costa LJ; Flinn IW; Inhorn L; Kelly K; Bessudo A; Fayad LE; Kaminski MS; Evens AM; Flowers CR; Sahin D; et al. (Leukemia & lymphoma, 2019)